Disclaimers This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended
ArGLP-1 con indicacin para obesidad Como se ha adelantado, existen dos arGLP-1 indicados para el tratamiento de la obesidad en la UE, en sujetos con IMC 30 kg/m2, o con IMC 27 kg/m2, y al menos una comorbilidad relacionada con el peso, siempre en combinacin con una dieta apropiada y ejercicio fsico: liraglutida 3 mg y semaglutida 2,4 mg
Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH, Hokken-Koelega AC
Some GLP-1 medications are FDA-approved to treat type 2 diabetes and used off-label for weight loss, while others are approved specifically to treat obesity
26, hitting the chemical company Monsanto with $2 billion in punitive damages in addition to $250 million in compensatory damages